Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mary Linn

Physician Assistant, Medical Van Buren, AR Physician Assistant

NPI 1013149798 CMS profile 11214589

620 Broadway St, Van Buren, AR 72956

Open in the dashboard

General payments

$6,146

383 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mary Linn of Van Buren, AR is reported in the CMS Open Payments database as having received $6,146 across 383 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $990 59
2024 General $1,116 59
2023 General $1,169 81
2022 General $1,130 71
2021 General $1,740 113

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mary Linn
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mary Linn were reported at $990. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mary Linn Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,740 $156 $41–$563 $132
2022 $1,130 $185 $55–$649 $149
2023 $1,169 $199 $58–$717 $160
2024 $1,116 $206 $62–$740 $164
2025 $990 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,203 90 payments
  2. AstraZeneca Pharmaceuticals LP $722 32 payments
  3. Novo Nordisk Inc $616 30 payments
  4. GlaxoSmithKline, LLC. $519 38 payments
  5. Amgen Inc. $483 33 payments
  6. Lilly USA, LLC $410 27 payments
  7. Pfizer Inc. $294 20 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $209 12 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $205 14 payments
  10. Otsuka America Pharmaceutical, Inc. $132 6 payments
  11. Other $1,352 81 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,052 382 payments
  2. Education $94 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $651 39 payments
  2. QULIPTA $542 35 payments
  3. RYBELSUS $539 25 payments
  4. TRELEGY ELLIPTA $491 36 payments
  5. Ozempic $456 26 payments
  6. Otezla $449 29 payments
  7. FARXIGA $437 13 payments
  8. VRAYLAR $295 32 payments
  9. BREZTRI $278 14 payments
  10. Repatha $277 17 payments
  11. Other $4,102 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 98 drugs

Part D claims

3,960

Median for Physician Assistant: 241

Drug cost

$246,141

Median for Physician Assistant: $4,110

Branded share of claims

23.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 40 $34,341
Mounjaro Tirzepatide Brand 31 $31,411
Ozempic Semaglutide Brand 29 $26,473
Xarelto Rivaroxaban Brand 23 $23,297
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 30 $18,332
Januvia Sitagliptin Phosphate Brand 18 $15,944
Jardiance Empagliflozin Brand 16 $9,746
Myrbetriq Mirabegron Brand 21 $9,408
Farxiga Dapagliflozin Propanediol Brand 15 $8,357
Tresiba Flextouch U-200 Insulin Degludec Brand 12 $7,294

The 10 drugs with the highest cost, of 98 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$16,976

Of which drugs: $1,500

Medicare patients

145

Average age 72

Services billed

506

111 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Depression 42%
Diabetes 30%
Ischemic heart disease 30%
Chronic kidney disease 22%
COPD 21%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 14 14 $1,126

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
$105 — —
UBRELVY
$80 — —
Otezla
$79 — —
Repatha
$79 — —
AIRSUPRA
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

383 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record